HRT+HEP – The perfect couple for a reliable glaucoma diagnosis

Article

Heidelberg Engineering is a high-tech medical device company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. It is a privately held company, headquartered in Heidelberg, Germany.

Heidelberg Engineering complements the gold standard of structural glaucoma diagnosis, the Heidelberg Retina Tomograph (HRT) with an innovative and reliable partner, the Heidelberg Edge Perimeter (HEP).

The HRT is a confocal laser scanning ophthalmoscope designed for the examination of the eye’s posterior pole. The integrated Moorfields Regression Analysis (MRA) classifies the optic nerve head (ONH) into healthy or glaucomatous by detecting diffuse and focal changes of the neuroretinal rim area.

Evaluating the central visual field, the HEP is designed for the use in early glaucoma detection as well as in progression analysis. The multi-functional HEP uses two different stimuli in one perimeter: the unique Flicker-Defined-Form (FDF) stimulus that creates an illusory “edge” contour and the well-known Standard Automated white-on-white Perimetry (SAP), that is useful in patients with moderate to severe disease and for continuity of care.

The new approach of HEP to visual fields was designed to work in combination with the well-established HRT. The Structure-Function Map (SF Map), a single report, is a combination of the HRT’s ability to classify significant change of the ONH and conjointly displays the given structural information with the functional information of the visual field.

http://www.heidelbergengineering.com/international/products/hep/structure-and-function-together-at-last/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.